Feature Channels: Immunology

Filters close
Released: 13-Feb-2024 11:05 AM EST
Life doesn't stop at age 65. Get the latest on seniors and healthy aging in the Seniors channel
Newswise

Below are some of the latest research and features on this growing population of older adults in the Seniors channel on Newswise.

Newswise: New Trial Highlights Incremental Progress Towards a Cure for HIV-1
Released: 13-Feb-2024 9:00 AM EST
New Trial Highlights Incremental Progress Towards a Cure for HIV-1
University of North Carolina School of Medicine

A new clinical trial, led by clinicians and researchers at the UNC School of Medicine, show that the combination of the drug vorinostat and immunotherapy may modestly shrink the latent HIV reservoir, but more work needs to be done in the field to create a cure.

12-Feb-2024 5:05 PM EST
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
University of Texas MD Anderson Cancer Center

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center

Newswise: Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
Released: 12-Feb-2024 11:55 AM EST
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
St. Jude Children's Research Hospital

Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.

Released: 12-Feb-2024 10:05 AM EST
Encefalite: Especialista da Mayo Clinic explica por que o tratamento precoce é importante
Mayo Clinic

A Encefalite é uma doença que envolve a inflamação ou inchaço do cérebro. Isso pode acontecer devido a infecções ou problemas no sistema imunológico, e o tratamento precoce é importante.

Released: 12-Feb-2024 10:05 AM EST
التهاب الدماغ: يشرح خبير من مايو كلينك سبب أهمية العلاج المبكر
Mayo Clinic

التهاب الدماغ هو مرض ينطوي على التهاب أو تورم الدماغ. ويمكن أن يحدث بسبب التهابات أو مشكلات تصيب الجهاز المناعي، والعلاج المبكر لتلك الحالة مهم. يقول ساروش إيراني، بكالوريوس الطب والجراحة.، طبيب الأعصاب، وباحث في مايو كلينك في جاكسونفيل، فلوريدا أنه لهذا السبب من الضروري رفع مستوى الوعي.

Released: 12-Feb-2024 10:05 AM EST
Encefalitis: Experto de Mayo Clinic explica por qué es importante el tratamiento temprano
Mayo Clinic

La Encefalitis es una enfermedad que implica inflamación o hinchazón del cerebro. Esto puede suceder debido a infecciones o problemas con el sistema inmunológico, y el tratamiento temprano es importante.

Released: 8-Feb-2024 8:50 AM EST
Atlantic Health System Enrolls First U.S. Patient in Lupus Treatment Trial
Atlantic Health System

NJ-based Atlantic Health System is the first in the U.S. to enroll a patient in a study to examine the effectiveness of using Chimeric Antigen Receptor (CAR- T) cells in the treatment of the autoimmune disease lupus.

Released: 7-Feb-2024 12:00 PM EST
Renowned Immunologist Dr. Gary Koretzky to Receive AAI Lifetime Achievement Award Honoring Exceptional Contributions to Immunology
American Association of Immunologists (AAI)

Recognizing the impact of his research and outstanding leadership in the field of immunology, Gary Koretzky, M.D., Ph.D., DFAAI (AAI ’92), will receive the American Association of Immunologists (AAI) Lifetime Achievement Award, the association’s highest honor, at the AAI annual conference IMMUNOLOGY2024TM, May 3-7 in Chicago.

   
Newswise: How T cells combat tuberculosis
Released: 6-Feb-2024 11:05 AM EST
How T cells combat tuberculosis
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology (LJI) have uncovered important clues to how human T cells combat the bacterium that causes tuberculosis.

Newswise: Immune networks in tumors prime responses to a personalized immunotherapy
Released: 6-Feb-2024 11:05 AM EST
Immune networks in tumors prime responses to a personalized immunotherapy
Ludwig Cancer Research

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).

1-Feb-2024 11:05 AM EST
Immune response, not acute viral infections, responsible for neurological damage, McMaster researchers discover
McMaster University

For years, there has been a long-held belief that acute viral infections like Zika or COVID-19 are directly responsible for neurological damage, but researchers from McMaster University have now discovered that it’s the immune system’s response that is behind it.

Released: 1-Feb-2024 10:05 PM EST
Gut bacteria can process dietary fiber into an anti-allergy weapon, finds new study
Tokyo University of Science

The intricate relationship that exists between humans and the gut microbiome has become a hot research topic, and scientists are constantly uncovering new reasons why a healthy diet can lead to a healthier life.

Newswise:Video Embedded live-event-nurses-the-most-trusted-profession-in-an-age-of-mistrust
VIDEO
Released: 1-Feb-2024 5:00 PM EST
VIDEO AND TRANSCRIPT: Nurses -- The Most Trusted Profession in an Age of Mistrust
Newswise

For 21 years, nurses have consistently been the most trusted profession, according to the yearly Gallup poll. (The new poll will be issued by the end of January). Dr Rushton, who specializes in burnout, will speak on trust, moral injury, and how nurses cope in this day and age.

Newswise:Video Embedded why-a-targeted-therapy-is-better-than-immunotherapy-for-some-patients-with-inoperable-non-small-cell-lung-cancer
VIDEO
Released: 31-Jan-2024 7:05 PM EST
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).

Released: 31-Jan-2024 5:05 PM EST
Molecule can quickly, and briefly, boost white blood cell counts
Yale University

Treatment with a molecule known as A485 can quickly and temporarily increase levels of white blood cells, a critical part of the body’s immune system, an effect that is difficult to deliver with currently available pharmaceuticals, a new Yale study finds.

Newswise: Brain Protein's Virus-Like Structure May Help Explain Cancer-Induced Memory Loss
24-Jan-2024 11:00 AM EST
Brain Protein's Virus-Like Structure May Help Explain Cancer-Induced Memory Loss
University of Utah Health

In a rare but serious complication of cancer, the immune system can start attacking the brain, causing rapid memory loss. What triggers this was largely unknown. Now, researchers at University of Utah Health have found that some tumors can release a virus-like protein, kickstarting an out-of-control autoimmune reaction.

Released: 30-Jan-2024 2:05 PM EST
Our winter of discontent: Get the latest news on the flu in the Influenza channel
Newswise

The latest research and expertise on the flue can be found in the Influenza channel on Newswise.

Newswise: National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Released: 30-Jan-2024 11:05 AM EST
National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year’s Barancik Prize for Innovation in MS Research.

Released: 30-Jan-2024 9:30 AM EST
Tomato juice’s antimicrobial properties can kill salmonella
American Society for Microbiology (ASM)

Tomato juice can kill Salmonella Typhi and other bacteria that can harm people's digestive and urinary tract health, according to research published this week in Microbiology Spectrum, a journal of the American Society for Microbiology.

   
Newswise:  New technology makes cancer easier for immune system to find and destroy
26-Jan-2024 7:00 AM EST
New technology makes cancer easier for immune system to find and destroy
Hokkaido University

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer.

Newswise: Immunologist Lydia Lynch appointed member of Ludwig Princeton
Released: 29-Jan-2024 1:05 PM EST
Immunologist Lydia Lynch appointed member of Ludwig Princeton
Ludwig Cancer Research

It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.

Released: 26-Jan-2024 4:05 PM EST
Ursula Storb, immunologist and role model for women scientists, 1936-2023
University of Chicago Medical Center

Storb was a Professor in the Department of Molecular Genetics and Cell Biology for more than 29 years.

Newswise:Video Embedded novel-immunotherapy-selectively-targets-malignant-t-cells
VIDEO
Released: 24-Jan-2024 3:05 PM EST
Novel Immunotherapy Selectively Targets Malignant T Cells
Yale Cancer Center/Smilow Cancer Hospital

One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.

Newswise: How the coronavirus defends itself against our immune system
Released: 24-Jan-2024 1:05 PM EST
How the coronavirus defends itself against our immune system
University of Göttingen

Over 700 million people were infected and almost seven million died, making SARS-CoV-2 the most devastating pandemic of the 21st century.

Newswise: Chemotherapy becomes more efficient when senescent cells are eliminated by immunotherapy
23-Jan-2024 9:30 AM EST
Chemotherapy becomes more efficient when senescent cells are eliminated by immunotherapy
Fundació Institut de Recerca Biomèdica (IRB BARCELONA)

Researchers from IRB Barcelona describe a mechanism by which senescent cells generated by chemotherapy survive inside tumours.

Newswise: RUDN doctors list pros and cons of treating inflammation with macrophages
Released: 22-Jan-2024 4:05 AM EST
RUDN doctors list pros and cons of treating inflammation with macrophages
Scientific Project Lomonosov

RUDN University doctors have studied how anti-inflammatory immune cells can help mitigate an excessive immune response. The authors discovered both positive and negative aspects of the new approach, but overall they proved its promise.

Newswise: Antibiotics highjack bacterial immunity
Released: 19-Jan-2024 12:05 PM EST
Antibiotics highjack bacterial immunity
Cluster of Excellence “Controlling Microbes to Fight Infections” (CMFI)

Molecular defense system protects bacteria from viruses and at the same time makes them susceptible to antibiotics.

18-Jan-2024 10:05 AM EST
McMaster researchers create instruction manual to detect rare cells that could unlock secrets to allergies
McMaster University

Researchers with McMaster University have created the instruction manual that will help scientists across the globe find hard to detect B cells.

Released: 19-Jan-2024 10:00 AM EST
American Society for Clinical Investigation elects six new members from Penn, CHOP
Perelman School of Medicine at the University of Pennsylvania

Six physician-scientists from the University of Pennsylvania Perelman School of Medicine and Children’s Hospital of Philadelphia have been elected to the American Society of Clinical Investigation, joining one of the nation’s oldest and most respected medical honor societies composed of more than 3,000 physician-scientists representing all medical specialties.

Newswise: Complement system causes cell damage in Long Covid
Released: 19-Jan-2024 7:05 AM EST
Complement system causes cell damage in Long Covid
University of Zurich

Most people infected with the SARS-CoV-2 virus recover after the acute illness.

Newswise:Video Embedded how-late-rising-t-cells-combat-a-stubborn-virus
VIDEO
Released: 18-Jan-2024 3:05 PM EST
How 'late-rising' T cells combat a stubborn virus
La Jolla Institute for Immunology

“We found sort of a special ‘flavor’ of CD4+ T cells critical for clearing this chronic virus replication,”

Released: 18-Jan-2024 2:05 PM EST
Researchers discover potentially cancer-fighting T cells within some pediatric brain tumor patients
La Jolla Institute for Immunology

"These patients may be candidates in whom immunotherapy has the potential to show clinical benefit."

Newswise: Analysis of brain tumor blood vessels yields a candidate therapy—and a platform to find more
Released: 18-Jan-2024 12:05 PM EST
Analysis of brain tumor blood vessels yields a candidate therapy—and a platform to find more
Ludwig Cancer Research

A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.

Newswise: When T cells and macrophages talk, Kelly Kersten listens
Released: 17-Jan-2024 2:05 PM EST
When T cells and macrophages talk, Kelly Kersten listens
Sanford Burnham Prebys

Kelly Kersten, Ph.D., who joined Sanford Burnham Prebys this month as an assistant professor in the Cancer Metabolism and Microenvironment program, studies the interactions between immune cells and their microenvironment to better understand how they contribute to anti-tumor immune responses.

Released: 17-Jan-2024 10:05 AM EST
Researchers Identify Key Characteristics Associated with Improved CAR T Outcomes in Large B Cell Lymphoma
Moffitt Cancer Center

Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% compared to standard therapy. Despite these positive outcomes in event-free survival and overall survival, some patients did not respond well to therapy or relapsed quickly after treatment. Researchers wanted to assess if there were specific tumor characteristics associated with improved outcomes that could better inform treatment selection. Their findings were published today in Nature Medicine.

Newswise: TTUHSC El Paso Researcher Receives Prestigious AACR Award, Spearheading Diversity in Cancer Research
Released: 17-Jan-2024 10:00 AM EST
TTUHSC El Paso Researcher Receives Prestigious AACR Award, Spearheading Diversity in Cancer Research
Texas Tech University Health Sciences Center El Paso

The award recognizes Dr. Chacon’s role as co-inventor of a licensed patent involving cancer immunotherapy.

Newswise: Bioengineered approach shows promise in ulcerative colitis
Released: 16-Jan-2024 10:05 AM EST
Bioengineered approach shows promise in ulcerative colitis
UT Southwestern Medical Center

By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.

15-Jan-2024 10:05 AM EST
New Covid variants learn old tricks to stay ahead of immune defences
University College London

Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from UCL.

Released: 12-Jan-2024 9:05 PM EST
Nutritional acquired immunodeficiency (N-AIDS) is the leading driver of the TB pandemic
Boston University School of Medicine

Tuberculosis (TB) is the leading infectious killer worldwide, with 10.6 million cases and 1.6 million deaths in 2021 alone. One in five incident TB cases were attributable to malnutrition, more than double the number attributed to HIV/AIDS.

Newswise: Studies examine different responses to SARS-CoV-2 variants
Released: 12-Jan-2024 12:05 PM EST
Studies examine different responses to SARS-CoV-2 variants
UT Southwestern Medical Center

Two studies led by a researcher at UT Southwestern Medical Center show the effects of different SARS-CoV-2 variants on lung tissue, revealing what may cause some COVID-19 infections to be more severe than others.

Not for public release

This news release is embargoed until 11-Jan-2024 1:00 PM EST Released to reporters: 4-Jan-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 11-Jan-2024 1:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 11-Jan-2024 10:05 AM EST
CD4+ T cell patterns linked to autoimmune disorders
Osaka University

Researchers from Osaka University find characteristic changes in CD4+ T cell categories and gene programs associated with autoimmune disease.

Released: 11-Jan-2024 8:05 AM EST
Higher viral load during HIV infection can shape viral evolution
Oxford University Press

A new paper in Molecular Biology and Evolution, published by Oxford University Press, finds that HIV populations in people with higher viral loads also have higher rates of viral recombination.

Newswise: Closing in on Triple-Negative Breast Cancer
Released: 9-Jan-2024 10:05 AM EST
Closing in on Triple-Negative Breast Cancer
Cedars-Sinai

Cedars-Sinai Cancer investigators have analyzed the cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with different responses to the treatment.

Released: 8-Jan-2024 4:05 PM EST
UTHealth Houston study: EBV-specific T-cells play key role in development of multiple sclerosis
University of Texas Health Science Center at Houston

The body’s immune response to Epstein-Barr virus (EBV) may play a role in causing damage in people with multiple sclerosis, according to a new study led by UTHealth Houston.

Newswise: When bad cells go good: Harnessing cellular cannibalism for cancer treatment
Released: 8-Jan-2024 3:05 PM EST
When bad cells go good: Harnessing cellular cannibalism for cancer treatment
University of California, Santa Barbara

Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency.

Newswise: Researchers identify why cancer immunotherapy can cause colitis
Released: 5-Jan-2024 2:10 PM EST
Researchers identify why cancer immunotherapy can cause colitis
Michigan Medicine - University of Michigan

Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment, also finding a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.



close
2.66583